Boots & Sabers

The blogging will continue until morale improves...


Everything but tech support.

2229, 07 Jun 21

FDA Approves Aducanumab


Aducanumab addresses Alzheimer’s in a new way compared to currently approved drugs. This therapy slows progression of the disease, rather than only addressing symptoms. It is the first approved therapy of this type; it demonstrates that removing amyloid from the brain may delay clinical decline in people living with Alzheimer’s. Amyloid is the protein that clumps into sticky brain plaques that are a hallmark of Alzheimer’s disease.


2229, 07 June 2021


  1. Mar

    First pallet to the White House.

  2. dad29

    Only $56K/year!!

  3. Mar

    Still cheaper than a nursing home room.

  4. Mar

    You’re right, Jonnyv, even the company testing did not produce good results. I wonder what happened in the past 2 years? Better results? Bribes? Relaxing of standards?

  5. dad29

    Given what we’ve learned about the FedGov in the last 5 years, massive bribes would NOT surprise me at all.

  6. Mar

    Yes, the same FDA that said Hydroxychloroquine didn’t work and oops, a major study now says it helped the severely I’ll patients, when taken with zinc helped improve the chances of survival by 200%.
    The FDA, media and Le Roi were wrong…again

Pin It on Pinterest